Merrimack CEO, CFO bow out, months after last clinical drug fizzles
Two months ago, Merrimack was forced to abandon its last drug in clinical trials, after an early-stage study showed that treatment with the drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
